Medifast 5 & 1 Plan
Randomized Controlled Trial of the Medifast 5 & 1 Plan
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- University of Alabama at Birmingham Division of Preventive Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI 35-50 kg/m2
- Interested in weight loss
- Computer with internet access
- Any race or ethnicity
- Fasting glucose <126 mg/dL at screening
Exclusion Criteria:
- Participation in any weight-reduction program, weight-loss diet, or other special diet within the previous 3 months.
- Weight loss or gain of >5% body weight in past 6 months for any reason except post-partum weight loss.
- Currently taking any medication that suppresses or stimulates appetite.
- History of prior surgical procedure for weight control or liposuction.
- Current smoker or quit smoking less than 6 months prior.
Any major disease, including:
- Active cancer or cancer requiring treatment in the past 2 years (except nonmelanoma skin cancer).
- Active or chronic infections, including self-reported HIV positivity and active tuberculosis.
- Active cardiovascular disease or event including hospitalization or therapeutic procedures for treatment of heart disease (e.g., coronary artery bypass, percutaneous transluminal coronary angioplasty) in the past 6 months; New York Heart Association Functional Class >2 with respect to congestive heart failure; stroke or transient ischemic attack in the past 6 months.
- Uncontrolled hypertension: systolic blood pressure >160 mm Hg or diastolic blood pressure >95 mm Hg on treatment.
- Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy).
- Active kidney disease.
- Lung disease: chronic obstructive airway disease requiring use of oxygen.
- Diagnosed diabetes (type 1 or 2), fasting hyperglycemia (blood glucose >126 mg/dL), or use of any anti-diabetic medications.
- Uncompensated or uncontrolled psychiatric disease (such as schizophrenia and bipolar disorder) that, in opinion of the investigators, would impede conduct of the trial or completion of procedures.
- A score on the Brief Symptom Inventory (BSI) (Derogatis & Melisaratos, 1983) that exceeds the 90th percentile.
- History of or current eating disorders, or an Eating Attitudes Test (EAT 40) score >30.
- Active food allergies, particularly to wheat, gluten, soy or nuts.
- Conditions or behaviors likely to effect the conduct of the trial: unable or unwilling to give informed consent; unable to communicate with the pertinent clinic staff; another household member is a participant or staff member in the trial; unwilling to accept treatment assignment by randomization; current or anticipated participation in another intervention research project that would interfere with the intervention offered in the trial; likely to move away from participating clinics before trial completed; unable to walk 0.25 mile in 10 minutes.
- Currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable.
- No regular source of health care.
- Any active use of illegal or illicit drugs or history of illegal or illicit drug utilization within past year
- Excessive alcohol intake, either acute or chronic defined as any one of the following: 1) average consumption of 3 or more alcohol containing beverages daily; 2) consumption of 7 or more alcoholic beverages within a 24-hr period in the past 12 months; or 3) other evidence available to clinic staff.
- Willing to limit alcohol intake to zero
- Pregnancy and childbearing: currently pregnant or less than 3 months post partum; currently nursing or within 6 weeks of having completed nursing; pregnancy anticipated during study; unwilling to report possible or confirmed pregnancies promptly during the course of the trial; unwilling to take adequate contraceptive measures if potentially fertile.
- Any other conditions which, in opinion of the investigators, would adversely affect the conduct of the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Food-based, Reduced Energy Diet Plan
|
Control participants will be provided with a 1000-kcal/d meal plan based on regular foods selected and procured by participants.
Food lists, sample menus, and portion size references will be provided.
|
|
Experimental: Medifast 5 & 1 Plan
|
Participants randomized to the Medifast group will enroll online in the Medifast 5 & 1 Plan.
This plan consists of 5 portion-controlled, nutritionally-balanced Medifast Meals plus one Lean & Green Meal each day.
Medifast Meals come in individual packets that are mixed with water and microwaved or refrigerated, and are available in a wide variety of foods and flavors.
There are >70 Medifast Meal choices, and Medifast Meals may be used interchangeably, so any five Medifast Meals can be chosen for the 5 & 1 Plan.
The Medifast 5 & 1 Plan provides approximately 800 to 1,000 kcal/d.
The Lean & Green Meal consists of a lean meat plus salad and/or vegetables selected by the participant.
Intervention participants will have online access to Medifast dietitians, Medifast trainers, a Medifast message board, and a Medifast chat room, allowing them to interact with others on the Medifast 5 & 1 Plan.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Body weight
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Waist circumference
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
Body composition as measured by bioelectrical impedence (BIA)
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
Body mass index
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
Low-density lipoprotein cholesterol (LDL)
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
High-density lipoprotein cholesterol (HDL)
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
Triglycerides
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
Glucose
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
Liver function tests
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
High-sensitivity C-reactive protein (hs-CRP)
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
Lipid hydroperoxides
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
Blood pressure
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
|
Appetite/satiety measures
Time Frame: 26 and 52 weeks
|
26 and 52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: David B. Allison, PhD., University of Alabama at Birmingham
- Principal Investigator: James M. Shikany, DrPH, University of Alabama at Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- F100625001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.